摘要
目的明确检测微小RNA-126对于评判小细胞肺癌(SCLC)预后的临床价值。方法纳入我院收治的SCLC患者,并进行为期12个月的随访以确认预后,比较不同预后患者组间各项指标的差异性;使用ROC进一步评判相应指标对于不良预后的评判价值。结果组间资料比较显示:主动吸烟史、肺癌遗传史、病理分型、Pro GRP、SCC、miRNA-126存在显著差异性(P均<0.05);其中广泛期SCLC、较高的Pro GRP、较高的miRNA-126显著影响其预后;ROC曲线显示上述2项肿瘤标志物评判SCLC患者发生不良预后的临界值分别为42.512 ng/L、1.6012-△△Ct。结论 miRNA-126对于评估SCLC不良预后具有良好的临床价值。
Objective To detect the clinical value of microRNA-126 for the evaluation of prognosis of small cell lung cancer （SCLC）. Methods SCLC patients in our hospital from July 1, 2013 to July 1, 2014 were follow-up for 12 months. Logistic regression analysis was used to screen independent risk factors, and ROC was used to judge the value of poor prognosis. Results The comparative data showed there were significant differences in active smoking history, lung cancer genetic history, pathological type, ProGRP, SCC, and miRNA-126 （P〈0. 05）, and extensive-stage SCLC, high ProGRP, and higher miRNA-126 affected the prognosis obviously. ROC curve showed two tumor markers above the critical value judgment poor prognosis in patients with SCLC were 42. 512 ng/L and 1. 6012-△△Ct . Conclusion MiRNA-126 has good clinical value on poor prognosis for NSCLC.
出处
《临床肺科杂志》
2016年第6期1102-1106,共5页
Journal of Clinical Pulmonary Medicine
